Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-66.38%
operating margin TTM
-65.38%
revenue TTM
40.57 Million
revenue per share TTM
0.88$
valuation ratios | |
|---|---|
| pe ratio | -8.40 |
| peg ratio | -0.04 |
| price to book ratio | 6.85 |
| price to sales ratio | 5.53 |
| enterprise value multiple | -11.03 |
| price fair value | 6.85 |
profitability ratios | |
|---|---|
| gross profit margin | 60.33% |
| operating profit margin | -65.38% |
| pretax profit margin | -71.69% |
| net profit margin | -66.38% |
| return on assets | -52.72% |
| return on equity | -63.4% |
| return on capital employed | -66.46% |
liquidity ratios | |
|---|---|
| current ratio | 3.74 |
| quick ratio | 3.64 |
| cash ratio | 2.80 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 24.70 |
| operating cycle | 84.86 |
| days of payables outstanding | 168.05 |
| cash conversion cycle | -83.19 |
| receivables turnover | 6.07 |
| payables turnover | 2.17 |
| inventory turnover | 14.78 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.15 |
| debt equity ratio | 0.24 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.19 |
| interest coverage | 12,027.95 |
| cash flow to debt ratio | -3.14 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.26 |
| cash per share | 0.30 |
| operating cash flow per share | -0.24 |
| free cash flow operating cash flow ratio | 1.07 |
| cash flow coverage ratios | -3.14 |
| short term coverage ratios | -25.88 |
| capital expenditure coverage ratio | -14.98 |
Frequently Asked Questions
When was the last time ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) reported earnings?
ImmunoPrecise Antibodies Ltd. (IPA) published its most recent earnings results on 12-03-2026.
What is ImmunoPrecise Antibodies Ltd.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA)'s trailing twelve months ROE is -63.4%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. ImmunoPrecise Antibodies Ltd. (IPA) currently has a ROA of -52.72%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did IPA's net profit margin stand at?
IPA reported a profit margin of -66.38% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is IPA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 3.74 in the most recent quarter. The quick ratio stood at 3.64, with a Debt/Eq ratio of 0.24.